SPADA Docs

absence in many other samples that do not contain the target (the exclusivity panel and the 68 matrix panel). In an ideal scenario, a laboratory routinely engaged in assay development could 69 complete this process within 6 months to 12 months. 70 Detection assays are typically designed using all sequences available at that time. Many of 71 the biodefense assays were designed and tested at least a decade ago when available sequences 72 were limited. Thanks to recent advances in modern sequencing technologies there is a sharp 73 increase in the availability of whole genome sequences (Figure 1). Hence, these older assays 74 have the potential to fail if evaluated against currently available sequences.

75 76

77 Figure 1. Availability of whole genome sequences for representative bacteria. Black bar 78 represents the assay design time frame.

79 80

Moreover, publicly available sequence databases (e.g., GenBank) typically contain only a 81 small fraction of naturally occurring sequence diversity. As a result, detection assays are 82

5